Alignment Healthcare (ALHC) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Veracyte (VCYT) has outperformed Alignment Healthcare (ALHC) over the past year, losing 42.9% versus a loss of 61.9%. Over five years, VCYT leads with a -39.5% price change compared with -63.3% for ALHC. Veracyte is the larger company by market cap ($2.03 billion vs $1.33 billion), about 1.5 times the size, while Alignment Healthcare is growing revenue faster (+46.1% vs +16.0%).
On valuation, Alignment Healthcare trades at a lower forward P/E (11.5x vs 16.2x for Veracyte). Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus -0.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALHC | VCYT |
|---|---|---|
| Share price | $6.37 | $25.13 |
| Market cap | $1.33B | $2.03B |
| 1-day change | -2.00% | +0.36% |
| YTD return | -67.75% | -40.31% |
| 1-year return | -61.86% | -42.90% |
| 5-year return | -63.26% | -39.53% |
| P/E ratio (TTM) | 45.50 | 16.32 |
| Forward P/E | 11.48 | 16.15 |
| EPS (TTM) | $0.14 | $1.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.95B | $517.14M |
| Revenue growth (YoY) | +46.06% | +16.01% |
| Net income (latest FY) | $-724.00K | $66.35M |
| Gross margin | — | 70.10% |
| Operating margin | 0.37% | 11.17% |
| Net margin | -0.02% | 12.83% |
| 52-week high | $25.12 | $60.91 |
| 52-week low | $6.01 | $21.91 |
| Distance from 52-week high | -74.64% | -58.74% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +69.39% | +77.48% |
| Average volume | 8.19M | 1.89M |
| Shares outstanding | 209.27M | 80.70M |
| Employees | 1,849 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VCYT has outperformed ALHC by 19.0 percentage points over the past year.
- Alignment Healthcare trades at a higher earnings multiple (45.5x vs 16.3x trailing P/E).
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -0.0 cents for Alignment Healthcare.
- Alignment Healthcare grew revenue faster in its latest fiscal year (+46.06% vs +16.01%).
About Alignment Healthcare
ALHC stock →Alignment Healthcare, Inc. operates a consumer-centric healthcare platform for seniors in the United States.
Health Care · Medical Specialities · 1,849 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
ALHC vs VCYT FAQ
Which is bigger, Alignment Healthcare or Veracyte?
Veracyte (VCYT) is larger, with a market capitalization of $2.03B compared with $1.33B for Alignment Healthcare (ALHC).
Which stock has performed better over the past year, ALHC or VCYT?
VCYT returned -42.90% over the past 12 months, compared with -61.86% for ALHC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALHC or VCYT?
VCYT has the lower trailing P/E at 16.3, versus 45.5 for ALHC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alignment Healthcare and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.